Tag: Lord Freyberg

The below Parliamentary question was asked by Lord Freyberg on 2015-11-26.

To ask Her Majesty’s Government what percentage of NHS secondary care centres provide third-party tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

Lord Prior of Brampton

All NHS England commissioned secondary and tertiary hospitals will be able to collect blood and/or tissue samples for the purpose of genetic testing, depending on the sampling technique required. The testing itself is however usually undertaken by commissioned genetic laboratories, which will typically serve a catchment area much greater than the hospital in which they are based. There will usually be recommended criteria in place to guide National Health Service referrals for genetic testing.

In a small number of cases, usually for very rare conditions, a test may need to be sent away to a non commissioned laboratory, including some abroad and some falling within the private sector, to access expertise. Funding will, however, continue to be provided from NHS budgets.

The United Kingdom is also leading the world by using cutting edge technology in the form of whole genome sequencing to transform healthcare and health research. The Prime Minister launched the 100,000 Genomes Project to bring the benefits of genome sequencing to NHS patients. The Project will sequence 100,000 whole human genomes of NHS patients with cancer or a rare disease by the end of 2017. Eleven Genomic Medicine Centres have been established across the country and are recruiting patients to this landmark project. Otherwise, NHS England does not hold data on private or self-funded care or testing commissioned from either NHS or third party laboratories.

Information on the percentage of eligible patients who received access to genetic testing is not held by NHS England. Due to data protection requirements, detailed data on the reasons for referral for specific tests are not currently aggregated at national level.

The below Parliamentary question was asked by Lord Freyberg on 2016-01-21.

To ask Her Majesty’s Government what are the costs, rather than the tariff, of a cancer molecular profile using (1) a whole tumour-normal pair using Illumina technology at 70× tumour coverage, and (2) a deep sequenced next-generation sequencing panel test, as deployed in most major NHS teaching hospitals; and if those figures are not available, why not.

Lord Prior of Brampton

This information is not held centrally by NHS England. Where the cost of these tests falls outside of tariff, costs will vary according to commissioning arrangements, the systems in place and the technology used.

Further information on the costs to the National Health Service of whole genome sequencing in cancer and rare diseases will be derived through the 100,000 Genomes Project. The intended NHS re-procurement of Regional Genetic Laboratories will aid in defining the costs of genomic tests.

The below Parliamentary question was asked by Lord Freyberg on 2016-02-22.

To ask Her Majesty’s Government why it was decided to use an 18-month period for patient reported outcomes in the next Prostate Cancer Audit rather than a six-month period, as used in Germany.

Lord Prior of Brampton

The proportion of men diagnosed with locally advanced prostate cancer between 2010 and 2013 (the Audit period) who had radical treatment, and the proportion who had a hospital length of stay over three days and who required an emergency readmission within 90 days following an operation, are presented by health region in the attached headed Table 1.

It should be noted that the results presented are based on an analysis of data from the English Cancer Registry linked to the Hospital Episode Statistics. These data were collected before the start of the National Prostate Cancer Audit (NPCA) in April 2013.

The number of radical prostatectomies undertaken in men diagnosed between 2010 and 2013, and the proportion of men who had a hospital length of stay over three days and who had an emergency readmission within 90 days following an operation, are presented in the attached headed Table 2. The results of 56 men included in the data set used to generate Figure 8 in the NPCA Annual Report 2015 could not be included in Table 2. Of these men, 37 were treated in National Health Service trusts that treated fewer than five patients during the Audit period; and for 19 patients it was not possible to identify the NHS trust where they had undergone treatment without incurring disproportionate cost.

The first results for the patient-reported outcomes of men who were diagnosed with prostate cancer between 1 April 2014 and 30 September 2014, and who underwent radical treatment (prostatectomy, external beam radiation, brachytherapy, cryotherapy, and high-intensity focused ultrasound), will be included in the NPCA’s Annual Report 2016, which is due to be published in the last quarter of 2016. These results will include incontinence rates.

Men who had radical prostate cancer treatment were invited to complete a questionnaire about their experiences of care as well as about treatment outcomes, 18 months after the date of diagnosis. It was decided that questionnaires should be sent out at this time after diagnosis because it can take more than one year for men who have radiotherapy, in combination with androgen deprivation therapy, to complete their treatment. Subsequently, it will take at least three months for men to fully recover from the transient side effects of the radiotherapy. In order to include all men and to measure the final treatment outcome – rather than outcomes still affected by the transient side effects – an 18-month period was chosen.

The below Parliamentary question was asked by Lord Freyberg on 2016-06-28.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 27 June (HL645), why no information is available of the number of patients who have died to date, particularly for those patients who consented prior to that answer.

Lord Prior of Brampton

Genomics England participants have consented to the collection of long term health data via the Health and Social Care Information Centre. This includes data on death but these data are collected and checked in accordance with standard procedures which means that there is a delay in linking to the whole genome sequencing data.